Paige, a digital pathology and AI leader, has introduced a service line powered by its Foundation Models. These models include the world’s largest multi-modal AI model for pathology and oncology. AI developers, organizations building computational pathology products, and life sciences companies can license and utilize these models to create their AI models for various purposes.
Paige Foundation Models eliminate the need for task-specific models, saving time and resources. They can adapt to various tasks without requiring individual training. Customers will have access to advanced pre-trained models, including Virchow, the largest image-based AI model for cancer detection, and PRISM, a multi-modal model with reporting and generative capabilities.
PRISM offers deep specificity and accuracy, allowing AI teams to analyze advanced cancer and rare biomarker detection, cellular subtyping, spatial biology, and therapy response prediction. Paige provides support and services to ensure partners maximize the potential of the Foundation Models.
Razik Yousfi, Paige’s Senior Vice President of Technology, indicated that their Foundation Models empower pharmaceutical companies with AI capabilities, revolutionizing drug discovery and development, and that licensees can reduce development time, build innovative AI applications, and enhance existing applications.
Andy Moye, Paige’s CEO, suggested that their goal is precision oncology, matching patients with the right treatments, and that their Foundation Models enable life sciences companies to advance drug discovery and improve treatment outcomes.
Paige uses AI to transform pathology. The company is committed to democratizing AI and empowering partners to innovate and advance cancer care.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
